JP2009528987A5 - - Google Patents

Download PDF

Info

Publication number
JP2009528987A5
JP2009528987A5 JP2008553534A JP2008553534A JP2009528987A5 JP 2009528987 A5 JP2009528987 A5 JP 2009528987A5 JP 2008553534 A JP2008553534 A JP 2008553534A JP 2008553534 A JP2008553534 A JP 2008553534A JP 2009528987 A5 JP2009528987 A5 JP 2009528987A5
Authority
JP
Japan
Prior art keywords
protein
yeast
influenza
antigen
composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2008553534A
Other languages
English (en)
Japanese (ja)
Other versions
JP5198290B2 (ja
JP2009528987A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2007/061572 external-priority patent/WO2007092792A2/en
Publication of JP2009528987A publication Critical patent/JP2009528987A/ja
Publication of JP2009528987A5 publication Critical patent/JP2009528987A5/ja
Application granted granted Critical
Publication of JP5198290B2 publication Critical patent/JP5198290B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2008553534A 2006-02-02 2007-02-02 免疫反応を誘発する酵母ベースワクチン Expired - Fee Related JP5198290B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US76502506P 2006-02-02 2006-02-02
US60/765,025 2006-02-02
PCT/US2007/061572 WO2007092792A2 (en) 2006-02-02 2007-02-02 Yeast-based vaccine for inducing an immune response

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2012260860A Division JP2013075899A (ja) 2006-02-02 2012-11-29 治療用組成物

Publications (3)

Publication Number Publication Date
JP2009528987A JP2009528987A (ja) 2009-08-13
JP2009528987A5 true JP2009528987A5 (enExample) 2010-04-02
JP5198290B2 JP5198290B2 (ja) 2013-05-15

Family

ID=38345897

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2008553534A Expired - Fee Related JP5198290B2 (ja) 2006-02-02 2007-02-02 免疫反応を誘発する酵母ベースワクチン
JP2012260860A Pending JP2013075899A (ja) 2006-02-02 2012-11-29 治療用組成物
JP2014230982A Withdrawn JP2015038147A (ja) 2006-02-02 2014-11-13 免疫反応を誘発する酵母ベースワクチン

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2012260860A Pending JP2013075899A (ja) 2006-02-02 2012-11-29 治療用組成物
JP2014230982A Withdrawn JP2015038147A (ja) 2006-02-02 2014-11-13 免疫反応を誘発する酵母ベースワクチン

Country Status (14)

Country Link
US (2) US7736642B2 (enExample)
EP (2) EP1988919A4 (enExample)
JP (3) JP5198290B2 (enExample)
KR (2) KR20140029551A (enExample)
CN (2) CN101405026B (enExample)
AU (1) AU2007212076B2 (enExample)
BR (1) BRPI0706913A2 (enExample)
CA (1) CA2638815A1 (enExample)
IL (2) IL193196A (enExample)
IN (1) IN2014DN08830A (enExample)
MX (1) MX2008009929A (enExample)
SG (2) SG169375A1 (enExample)
TW (2) TW201412329A (enExample)
WO (1) WO2007092792A2 (enExample)

Families Citing this family (63)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2002225681A1 (en) * 2000-11-15 2002-05-27 Globe Immune, Inc. Yeast-dentritic cell vaccines and uses thereof
JP4914990B2 (ja) 2002-12-16 2012-04-11 グローブイミューン，インコーポレイテッド 動物を癌から守るための治療用組成物
US8343502B2 (en) * 2002-12-16 2013-01-01 Globeimmune, Inc. Yeast-based vaccines as immunotherapy
WO2007008780A2 (en) * 2005-07-11 2007-01-18 Globeimmune, Inc. Compositions and methods for eliciting an immune response to escape mutants of targeted therapies
US20070172503A1 (en) * 2005-12-13 2007-07-26 Mycologics,Inc. Compositions and Methods to Elicit Immune Responses Against Pathogenic Organisms Using Yeast Based Vaccines
CA2638815A1 (en) * 2006-02-02 2007-08-16 Globeimmune, Inc. Yeast-based vaccine for inducing an immune response
GB0613977D0 (en) 2006-02-07 2006-08-23 Peptcell Ltd Peptide sequences and compositions
WO2007130330A2 (en) * 2006-05-01 2007-11-15 Technovax, Inc. Polyvalent influenza virus-like particle (vlp) compositions
US20100143393A1 (en) * 2006-05-11 2010-06-10 Gale Smith Novel influenza m2 vaccines
EP2023952B1 (en) * 2006-05-18 2015-07-15 Epimmune Inc. Inducing immune responses to influenza virus using polypeptide and nucleic acid compositions
CN101687030B (zh) * 2007-02-02 2014-07-02 环球免疫公司 用于生产基于酵母的疫苗的方法
WO2008115610A1 (en) * 2007-03-19 2008-09-25 Globeimmune, Inc. Compositions and methods for targeted ablation of mutational escape of targeted therapies for cancer
US20100285050A1 (en) 2007-10-05 2010-11-11 Isis Innovation Limited Compositions and Methods
GB0719526D0 (en) * 2007-10-05 2007-11-14 Isis Innovation Compositions and methods
US20110177122A1 (en) * 2008-09-26 2011-07-21 The United States Of America, As Represented By The Secretary, Dept. Of Health & Human Services Dna prime/activated vaccine boost immunization to influenza virus
ES2660597T3 (es) 2009-04-17 2018-03-23 Globeimmune, Inc. Composiciones inmunoterápicas de combinación contra el cáncer y métodos
EP2432503A4 (en) * 2009-05-18 2013-01-23 Panacea Biotec Ltd BASED ON RECOMBINANTLY MODIFIED VACCINIA ANKARA VIRUS UNIVERSAL GRIP VACCINATE
US8911722B2 (en) 2009-09-14 2014-12-16 The Regents Of The University Of Colorado, A Body Corporate Modulation of yeast-based immunotherapy products and responses
WO2012006561A2 (en) * 2010-07-08 2012-01-12 New York Medical College Influenza virus detection and diagnosis
AU2011312178B2 (en) * 2010-10-04 2016-05-12 Massachusetts Institute Of Technology Hemagglutinin polypeptides, and reagents and methods relating thereto
US9173933B2 (en) * 2010-10-15 2015-11-03 Bavarian Nordic A/S Recombinant modified vaccinia virus Ankara influenza vaccine
EP2651439B1 (en) 2010-12-17 2018-09-19 Globeimmune, Inc. Compositions and methods for the treatment or prevention of human adenovirus-36 infection
JP6169494B2 (ja) * 2011-01-31 2017-07-26 ナノセラピューティクス・インコーポレイテッドＮａｎｏｔｈｅｒａｐｅｕｔｉｃｓ， Ｉｎｃ． インフルエンザａウイルスに対するヘテロサブタイプ免疫応答を誘導するための組換えウイルスベクターおよび方法
PE20140844A1 (es) 2011-02-12 2014-07-14 Globeimmune Inc Terapeuticos a base de levadura para infeccion de la hepatitis b cronica
JP6068368B2 (ja) 2011-03-17 2017-01-25 グローブイミューン，インコーポレイテッド 酵母−ブラキュリ免疫治療組成物
US20140377295A1 (en) * 2011-05-23 2014-12-25 The Wistar Institute Of Anatomy And Biology Influenza vaccines containing modified adenovirus vectors
EP2720716B1 (en) 2011-06-14 2018-03-21 Globeimmune, Inc. Immunotherapeutic compositions for the treatment or prevention of hepatitis delta virus infection
EP2721158B1 (en) * 2011-06-20 2017-05-03 University of Pittsburgh - Of the Commonwealth System of Higher Education Computationally optimized broadly reactive antigens for h1n1 influenza
CN109010809A (zh) 2011-08-17 2018-12-18 全球免疫股份有限公司 酵母-muc1免疫治疗组合物及其用途
EP2591798B1 (en) * 2011-11-09 2014-11-19 Werner Lubitz Vaccine for use in tumor immunotherapy
DE102011121069A1 (de) 2011-12-13 2013-06-13 Martin-Luther-Universität Halle-Wittenberg Vakzinierung mittels rekombinanter Hefe durch Erzeugung einer protektiven humoralen Immunantwort gegen definierte Antigene
KR102103319B1 (ko) 2012-06-26 2020-04-22 바이오디식스, 인크. 면역반응 발생 요법으로 치료하기 위해 암환자들의 선택, 및 선택해제를 위한 질량-스펙트럼법
US20140065173A1 (en) 2012-09-06 2014-03-06 Orbis Health Solutions Llc Tumor lysate loaded particles
JP5954079B2 (ja) 2012-09-25 2016-07-20 ソニー株式会社 培養観察装置及び培養観察方法
AU2013359469B2 (en) * 2012-12-10 2019-05-16 Seattle Biomedical Research Institute Cell-free biofragment compositions and related systems, devices, and methods
AU2014235120B2 (en) * 2013-03-15 2017-01-05 The Trustees Of The University Of Pennsylvania Vaccines having an antigen and interleukin-23 as an adjuvant
MX374829B (es) 2013-03-19 2025-03-06 Globeimmune Inc Composición a base de levadura para usarse para tratar cordoma.
US9782473B2 (en) 2013-03-26 2017-10-10 Globeimmune, Inc. Compositions and methods for the treatment or prevention of human immunodeficiency virus infection
JP2014210747A (ja) * 2013-04-19 2014-11-13 アンジェスＭｇ株式会社 細胞性免疫誘導能が改善された経口ワクチン
TWI654200B (zh) * 2013-08-30 2019-03-21 環球免疫公司 治療或預防結核病的組合物及方法
WO2015103602A1 (en) * 2014-01-06 2015-07-09 The Trustees Of The University Of Pennsylvania Pd1 and pdl1 antibodies and vaccine combinations and use of same for immunotherapy
EP3113759B1 (en) 2014-03-05 2021-05-12 Orbis Health Solutions LLC Vaccine delivery systems using yeast cell wall particles
CA2948803A1 (en) 2014-04-11 2015-10-15 Globeimmune, Inc. Yeast-based immunotherapy and type i interferon sensitivity
CN105233302B (zh) * 2014-07-10 2018-10-19 中国人民解放军军事医学科学院生物工程研究所 一种流感血凝素糖蛋白多聚物纳米颗粒的制备方法
US10695417B2 (en) 2015-01-09 2020-06-30 Etubics Corporation Human adenovirus serotype 5 vectors containing E1 and E2B deletions encoding the ebola virus glycoprotein
WO2016168187A1 (en) * 2015-04-13 2016-10-20 The Regents Of The University Of Michigan Virus-like particles
TWI748957B (zh) 2015-08-03 2021-12-11 美商環球免疫公司 經修飾之酵母-短尾畸型（Ｂｒａｃｈｙｕｒｙ）免疫治療組合物
WO2017027568A1 (en) * 2015-08-11 2017-02-16 Orbis Health Solutions Llc Bacterial and viral vaccine strategy
GB2552441A (en) * 2015-10-22 2018-01-31 Royal Veterinary College Methods
EP3195878A1 (en) 2016-01-22 2017-07-26 Werner Lubitz Bacterial ghosts for the treatment of cancer
JP2019513021A (ja) 2016-03-24 2019-05-23 ナントセル，インコーポレイテッド ネオエピトープ提示のための配列の配置および配列
CA3061240C (en) 2017-04-24 2024-01-16 Nantcell, Inc. Targeted neoepitope vectors and methods therefor
CA3086456A1 (en) 2017-12-21 2019-06-27 Kirin Holdings Kabushiki Kaisha Cross-immunizing antigen vaccine and method for preparation thereof
DE102017012109A1 (de) * 2017-12-27 2019-06-27 Martin-Luther-Universität Halle-Wittenberg Optimiertes Wirts-/Vektorsystem zur Erzeugung protektiver mono- und multivalenter subunit-Vakzine auf Basis der Hefe Kluyveromyces lactis
CN119818663A (zh) * 2018-05-15 2025-04-15 全球免疫公司 用于诱导细胞免疫应答的重组酵母裂解物
US12239699B2 (en) * 2018-09-11 2025-03-04 Shanghai Public Health Clinical Center Immunogen for broad-spectrum influenza vaccine and application thereof
US20210290708A1 (en) 2018-09-21 2021-09-23 Nantcell, Inc. Methods and compositions for modulating myeloid-derived suppressor cells
BR112021023348A2 (pt) * 2019-05-21 2022-02-01 Esperovax Inc Vacinação oral à base de levedura
WO2021163222A1 (en) * 2020-02-11 2021-08-19 Cytonus Therapeutics, Inc. Rapid vaccine platform
US12285480B2 (en) 2020-03-11 2025-04-29 Nantcell, Inc. Method of inducing immunity against SARS-CoV-2 using spike and nucleocapsid-ETSD immunogens delivered by RNA and replication-defective adenoviruses
US11857620B2 (en) 2020-03-11 2024-01-02 Immunitybio, Inc. Method of inducing immunity against SARS-CoV-2 using spike (s) and nucleocapsid (N)-ETSD immunogens delivered by a replication-defective adenovirus
US20210284716A1 (en) 2020-03-11 2021-09-16 Immunitybio, Inc. ACE2-Fc Trap
CA3170359A1 (en) 2020-04-14 2021-10-21 Nantcell, Inc. Yeast lysate covid-19 vaccine

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5413914A (en) 1993-07-07 1995-05-09 The Regents Of The University Of Colorado Yeast assay to identify inhibitors of dibasic amino acid processing endoproteases
US5830463A (en) 1993-07-07 1998-11-03 University Technology Corporation Yeast-based delivery vehicles
JPH09511381A (ja) 1994-01-11 1997-11-18 ブラームス・インターユニバージテーア・インスティテュート・ボーア・ビーオテクノロジー インフルエンザワクチン
US5691189A (en) * 1994-01-19 1997-11-25 Bristol-Myers Squibb Company Saccharomyces cerevisiae expressing M2 protein of influenza A virus
US6696251B1 (en) * 1996-05-31 2004-02-24 Board Of Trustees Of The University Of Illinois Yeast cell surface display of proteins and uses thereof
US20020044948A1 (en) * 2000-03-15 2002-04-18 Samir Khleif Methods and compositions for co-stimulation of immunological responses to peptide antigens
ATE376059T1 (de) * 2000-06-23 2007-11-15 Wyeth Corp Assemblierung von wildtyp und chimären influenzavirus-ähnlichen partikeln (vlps)
AU2002225681A1 (en) 2000-11-15 2002-05-27 Globe Immune, Inc. Yeast-dentritic cell vaccines and uses thereof
US20030008000A1 (en) * 2001-03-08 2003-01-09 Wong Jonathan P. DNA vaccine using liposome-encapsulated plasmid DNA encoding for hemagglutinin protein of influenza virus
US20030202982A1 (en) 2001-08-15 2003-10-30 Birkett Ashley J. Influenza immunogen and vaccine
US7439042B2 (en) * 2002-12-16 2008-10-21 Globeimmune, Inc. Yeast-based therapeutic for chronic hepatitis C infection
JP4914990B2 (ja) * 2002-12-16 2012-04-11 グローブイミューン，インコーポレイテッド 動物を癌から守るための治療用組成物
US8592197B2 (en) * 2003-07-11 2013-11-26 Novavax, Inc. Functional influenza virus-like particles (VLPs)
JP5331340B2 (ja) * 2004-05-18 2013-10-30 バイカル インコーポレイテッド インフルエンザウィルスワクチン組成物、及びその使用方法
AU2005284727A1 (en) 2004-09-17 2006-03-23 University Of Massachusetts Compositions and their uses for lysosomal enzyme deficiencies
CA2638815A1 (en) * 2006-02-02 2007-08-16 Globeimmune, Inc. Yeast-based vaccine for inducing an immune response

Similar Documents

Publication Publication Date Title
Pardi et al. Development of a pentavalent broadly protective nucleoside-modified mRNA vaccine against influenza B viruses
Freyn et al. A multi-targeting, nucleoside-modified mRNA influenza virus vaccine provides broad protection in mice
Wohlbold et al. Vaccination with soluble headless hemagglutinin protects mice from challenge with divergent influenza viruses
IL193196A (en) Vaccine comprising a yeast vehicle and an influenza virus fusion protein
Gerhard et al. Prospects for universal influenza virus vaccine
Song et al. Influenza virus-like particles containing M2 induce broadly cross protective immunity
Branco et al. Lassa virus-like particles displaying all major immunological determinants as a vaccine candidate for Lassa hemorrhagic fever
US11191727B2 (en) Multivalent nanoparticle-based vaccines
Gao et al. Enhanced Influenza VLP vaccines comprising matrix-2 ectodomain and nucleoprotein epitopes protects mice from lethal challenge
Deng et al. M2e-based universal influenza A vaccines
Kim et al. Multiple heterologous M2 extracellular domains presented on virus-like particles confer broader and stronger M2 immunity than live influenza A virus infection
Lee et al. Mechanisms of cross-protection by influenza virus M2-based vaccines
Deliyannis et al. Induction of long-term memory CD8+ T cells for recall of viral clearing responses against influenza virus
Arunkumar et al. Vaccination with viral vectors expressing NP, M1 and chimeric hemagglutinin induces broad protection against influenza virus challenge in mice
Epstein Universal influenza vaccines: progress in achieving broad cross-protection in vivo
HRP20171213T1 (hr) Glikoproteinske čestice nalik virusu (vlp) bjesnoće
Stepanova et al. Flagellin-fused protein targeting M2e and HA2 induces potent humoral and T-cell responses and protects mice against various influenza viruses a subtypes
JP2014507144A5 (ja) 慢性ｂ型肝炎感染症のための酵母系免疫療法組成物
EP3199545A3 (en) Computationally optimized broadly reactive antigens for h1n1 influenza
Choi et al. Chromatographically-purified capsid proteins of red-spotted grouper nervous necrosis virus expressed in Saccharomyces cerevisiae form virus-like particles
Bolduc et al. The quest for a nanoparticle-based vaccine inducing broad protection to influenza viruses
Trucchi et al. Universal influenza virus vaccines: what needs to happen next?
Yong et al. Development of virus‐like particles‐based vaccines against coronaviruses
Prokopenko et al. Truncation of NS1 protein enhances T cell-mediated cross-protection of a live attenuated influenza vaccine virus expressing wild-type nucleoprotein
Feng et al. Baculovirus surface display of SARS coronavirus (SARS-CoV) spike protein and immunogenicity of the displayed protein in mice models